New studies support effectiveness of non-invasive genomic testing across many cancer types

Guardant Health, creators of the Guardant360® liquid biopsy test, recently announced the publication of two peer-reviewed studies that suggest superior performance over traditional tissue biopsy tests.

Links to the two studies are available here, and here.

Asia Genomics offers the Guardant360® test as part of our portfolio. Contact us for more information.